Literature DB >> 15660192

Radiobiological investigation of dose-rate effects in intensity-modulated radiation therapy.

Florian Sterzing1, Marc W Münter, Mattias Schäfer, Peter Haering, Bernhard Rhein, Christoph Thilmann, Jürgen Debus.   

Abstract

BACKGROUND AND
PURPOSE: Intensity-modulated radiation therapy (IMRT) has proven extraordinary capability in physical terms such as target conformity, dose escalation in the target volume, and sparing of neighboring organs at risk. The radiobiological consequences of the protracted dose delivery for cell survival and cell cycle progression are still unclear and shall be examined in this study.
MATERIAL AND METHODS: Human lymphoblasts (TK6) and human melanoma cells (MeWo) were irradiated with protocols of increasing dose protraction. In addition, a new biophysical phantom was developed and used to transfer clinical IMRT plans to experimental cell irradiation. Clonogenic cell survival and cell cycle analysis were performed after various irradiation experiments.
RESULTS: In a first series of experiments, melanoma cells showed a highly significant increase of survival of 6.0% after protracted dose delivery of 2 Gy compared to conventional fast application with the same dose. Lymphoblastoid cells also showed a significant increase of survival of 2.2%. Experiments with patient plans in the phantom confirmed the trend of increased cell survival after protracted dose delivery. Cells were irradiated at 13 points in four different IMRT plans. In comparison to irradiation with application of the same dose in a classic four-field box, a significantly increased survival of 5.1% (mean value) was determined.
CONCLUSION: Even at fraction times of 15-30 min the protracted dose delivery increases the survival rates in cell culture. The altered survival rates indicate the importance of the dose rate in the effectivity of IMRT. Besides physical parameters the consideration of biological factors might contribute to the optimization of IMRT in the future.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15660192     DOI: 10.1007/s00066-005-1290-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  10 in total

1.  Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy.

Authors:  Florian Sterzing; Thomas B Brunner; Iris Ernst; Wolfgang W Baus; Burkhard Greve; Klaus Herfarth; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2014-08-05       Impact factor: 3.621

2.  Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo.

Authors:  Frank Michael Klenke; Amir Abdollahi; Marc Bischof; Martha-Maria Gebhard; Volker Ewerbeck; Peter E Huber; Axel Sckell
Journal:  Strahlenther Onkol       Date:  2010-12-23       Impact factor: 3.621

3.  Impact of decaying dose rate in gamma knife radiosurgery: in vitro study on 9L rat gliosarcoma cells.

Authors:  Ajay Niranjan; Glenn Gobbel; Josef Novotny; Jagdish Bhatnagar; Wendy Fellows; L Dade Lunsford
Journal:  J Radiosurg SBRT       Date:  2012

4.  Effect of prolonging radiation delivery time on retention of gammaH2AX.

Authors:  Vitali Moiseenko; Judit P Banáth; Cheryl Duzenli; Peggy L Olive
Journal:  Radiat Oncol       Date:  2008-06-27       Impact factor: 3.481

5.  In vivo measurement of dose distribution in patients' lymphocytes: helical tomotherapy versus step-and-shoot IMRT in prostate cancer.

Authors:  Felix Zwicker; Benedict Swartman; Falk Roeder; Florian Sterzing; Henrik Hauswald; Christian Thieke; Klaus-Josef Weber; Peter E Huber; Kai Schubert; Jürgen Debus; Klaus Herfarth
Journal:  J Radiat Res       Date:  2014-10-31       Impact factor: 2.724

6.  Impact of time interval and dose rate on cell survival following low-dose fractionated exposures.

Authors:  Shingo Terashima; Yoichiro Hosokawa; Eichi Tsuruga; Yasushi Mariya; Toshiya Nakamura
Journal:  J Radiat Res       Date:  2017-11-01       Impact factor: 2.724

7.  Impact of Prolonged Fraction Delivery Time Modelling Stereotactic Body Radiation Therapy with High Dose Hypofractionation on the Killing of Cultured ACHN Renal Cell Carcinoma Cell Line.

Authors:  M Khorramizadeh; A Saberi; Ma Tahmasebi-Birgani; P Shokrani; A Amouhedari
Journal:  J Biomed Phys Eng       Date:  2017-09-01

8.  Intensity Modulated Radiotherapy (IMRT) and Fractionated Stereotactic Radiotherapy (FSRT) for children with head-and-neck-rhabdomyosarcoma.

Authors:  Stephanie E Combs; Wolfgang Behnisch; Andreas E Kulozik; Peter E Huber; Jürgen Debus; Daniela Schulz-Ertner
Journal:  BMC Cancer       Date:  2007-09-13       Impact factor: 4.430

9.  Low Hepatic Toxicity in Primary and Metastatic Liver Cancers after Stereotactic Ablative Radiotherapy Using 3 Fractions.

Authors:  Sun Hyun Bae; Mi-Sook Kim; Won Il Jang; Chul Koo Cho; Hyung Jun Yoo; Kum Bae Kim; Chul Ju Han; Su Cheol Park; Dong Han Lee
Journal:  J Korean Med Sci       Date:  2015-07-15       Impact factor: 2.153

Review 10.  Clinical utility of RapidArc™ radiotherapy technology.

Authors:  Erminia Infusino
Journal:  Cancer Manag Res       Date:  2015-11-12       Impact factor: 3.989

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.